[1] Chalmers AJ,Lakshman M,Chan N,et al. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol,2010,20:274-281. [2] Meyn RE,Munshi A,Haymach JV,et al. Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol,2009,92:316-322. [3] Jorgensen TJ. Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther,2009,8:665-670. [4] Fernet M,Hall J. Genetic biomarkers of therapeutic radiation sensitivity. DNA Repair,2004,3:1237-1243. [5] Powell C,Mikropoulos C,Kaye SB,et al. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev,2010,36:566-575. [6] Leung M,Rosen D,Fields S,et al. Poly(ADP-ribose) polymerase-1 Inhibition: preclinical and clinical development of synthetic lethality. Mol Med,2011,In press. [7] Drew Y,Plummer R. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. Curr Opin Obstet Gynecol,2010,22:67-71. [8] Tutt A,Robson M,Garber JE,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet,2010,376:235-244. [9] Calabrese CR,Almassy R,Barton S,et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst,2004,96:56-67. [10] Albert JM,Cao C,Kim KW,et al. Inhibition of poly(ADPribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res,2007,13:3033-3042. [11] Russo AL,Kwon HC,Burgan WE,et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly(ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res,2009,15:607-612. [12] Liu SK,Coackley C,Krause M,et al. A novel poly(ADPribose) polymerase inhibitor,ABT-888,radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol,2008,88:258-268. [13] Dungey FA,Lser DA,Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: Mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys,2008,72:1188-1197. [14] Loser DA,Shibata A,Shibata AK,et al. Chalmers: Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther,2010,9:1775-1787.
[15] Donawho CK,Luo Y,Penning TD,et al. ABT-888,an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res,2007,13:2728-2737. [16] Khan K,Araki K,Wang D,et al. Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck,2010,32:381-391. [17] Chalmers A,Johnston P,Woodcock M,et al. PARP-1,PARP-2,and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys,2004,58:410-419. [18] Nol G,Godon C,Fernet M,et al. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther,2006,5:564-574. [19] Arundel-Suto CM,Scavone SV,Turner WR,et al. Effect of PD 128763,a new and potent inhibitor of poly(ADP-ribose) polymerase,on X-ray induced cellular recovery processes in Chinese hamster V79 cells. Radiat Res,1991,126:367-371. [20] Rudat V,Küpper JH,Weber KJ.Trans-dominant inhibition of poly(ADPribosyl) ation leads to decreased recovery from ionizing radiation-induced cell killing. Int J Radiat Biol,1998,73:325-330. [21] Weichselbaum RR. Radioresistant and repair proficient cells may determine radiocuribility in human tumours. Int J Radiat Oncol Biol Phys,1986,12:637-639. [22] Veuger SJ,Curtin NJ,Richardson CJ,et al. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res,2003,63:6008-6015. [23] Fukushima M,Kuzuya K,Ota K,et al. Poly(ADP-ribose) synthesis in human cervical cancer cell-diagnostic cytological usefulness. Cancer Lett,1981,14:227-236. [24] Horton JK,Stefanick DF,Wilson SH. Involvement of poly(ADPribose) polymerase activity in regulating Chk1-dependent apoptotic cell death. DNA Repair,2005,4:1111-1120. [25] Efimova EV,Mauceri HJ,Golden DW,et al. Poly(ADP-Ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res,2010,70:6277-6282. [26] Seigneuric R,Starmans MH,Fung G,et al. Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol,2007,83:374-782. [27] Kraus W,Lis J. PARP goes transcription. Cell,2003,113:677-683. [28] Veuger SJ,Hunter JE,Durkacz BW. Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance. Oncogene,2009,28:832-842. [29] Mangerich A,Bürkle A. How to kill tumor cells with inhibitors of poly(ADP-ribosyl) ation-OK. Int J Cancer,2011,128:251-265. [30] Horsman MR. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Acta Oncol,1995,34:571-587. [31] Fong PC,Boss DS,Yap TA,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med,2009,361:123-134.
2012, Vol. 21 
